Overall Survival in Key Trials
Ruxolitinib plus azacitidine improved overall survival compared to azacitidine alone in patients with higher-risk myelodysplastic syndromes (HR-MDS) in the phase 3 INSPIRE trial. Median OS was 19.2 months with the combination versus 15.2 months with azacitidine monotherapy (HR 0.77, 95% CI 0.59-1.00; p=0.051). In the phase 3 COMFORT trials for myelofibrosis, ruxolitinib monotherapy reduced spleen volume and improved survival (median OS not reached vs 15 months with placebo/best available therapy at 3 years; HR 0.50).[1][2]
Response Rates and Spleen Reduction
In INSPIRE, complete remission rates were higher with ruxolitinib + azacitidine (33.3% vs 24.0%), alongside better transfusion independence (52.5% vs 42.5%). Ruxolitinib excels in spleen volume reduction—45% reduction at 24 weeks in COMFORT-I/II vs 0.7% with placebo—addressing a key symptom azacitidine does not target effectively in MDS or myelofibrosis.[1][3]
Progression to Acute Myeloid Leukemia
Ruxolitinib + azacitidine delayed AML progression in HR-MDS patients (17.4% vs 22.6% at 18 months in INSPIRE), though azacitidine alone remains a standard for delaying transformation in lower-risk MDS.[1]
Safety and Adverse Events
Both carry myelosuppression risks, but ruxolitinib adds thrombocytopenia (49% grade 3/4 vs 38% with azacitidine alone) and infections. Azacitidine monotherapy has higher nausea (up to 70%). Discontinuation due to adverse events was similar (20-25%) in head-to-head data.[1][4]
When Are Outcomes Better with One Over the Other?
Ruxolitinib shines in JAK2-mutated myelofibrosis or symptomatic splenomegaly; azacitidine suits TP53-mutated MDS without JAK activation. Combination therapy benefits intermediate-2/high-risk MDS but increases toxicity.[2][5]
[1]: NEJM - INSPIRE Trial (2022)
[2]: DrugPatentWatch.com - Ruxolitinib Patents
[3]: Lancet Oncology - COMFORT-II (2013)
[4]: AZA-001 Trial, Lancet (2010)
[5]: NCCN Guidelines, Myelodysplastic Syndromes (v2.2023)